Cellectis S.A. (CLLS)
USD 1.59
(-1.18%)
USD 1.59
(-1.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 249.57 Million USD | 84.49% |
| 2022 | 135.27 Million USD | -7.09% |
| 2021 | 145.6 Million USD | -9.35% |
| 2020 | 160.62 Million USD | 43.42% |
| 2019 | 111.99 Million USD | 121.48% |
| 2018 | 50.56 Million USD | 7.64% |
| 2017 | 46.97 Million USD | -17.05% |
| 2016 | 56.63 Million USD | -33.11% |
| 2015 | 84.66 Million USD | -10.83% |
| 2014 | 94.95 Million USD | 153.46% |
| 2013 | 37.46 Million USD | 12.1% |
| 2012 | 33.41 Million USD | -64.77% |
| 2011 | 94.86 Million USD | 396.58% |
| 2010 | 19.1 Million USD | 5.44% |
| 2009 | 18.11 Million USD | 23.92% |
| 2008 | 14.62 Million USD | 41.54% |
| 2007 | 10.32 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 258.53 Million USD | -2.03% |
| 2024 Q1 | 263.89 Million USD | 5.74% |
| 2023 Q1 | 130.91 Million USD | -3.22% |
| 2023 FY | 249.57 Million USD | 84.49% |
| 2023 Q3 | 133.57 Million USD | 1.88% |
| 2023 Q2 | 131.11 Million USD | 0.15% |
| 2023 Q4 | 249.57 Million USD | 86.84% |
| 2022 Q1 | 144.13 Million USD | -1.01% |
| 2022 FY | 135.27 Million USD | -7.09% |
| 2022 Q4 | 135.27 Million USD | 0.98% |
| 2022 Q3 | 133.96 Million USD | -4.56% |
| 2022 Q2 | 140.36 Million USD | -2.62% |
| 2021 Q2 | 155.24 Million USD | 1.49% |
| 2021 Q4 | 145.6 Million USD | -3.41% |
| 2021 FY | 145.6 Million USD | -9.35% |
| 2021 Q1 | 152.96 Million USD | -4.77% |
| 2021 Q3 | 150.73 Million USD | -2.9% |
| 2020 Q2 | 127.63 Million USD | 26.94% |
| 2020 Q4 | 160.62 Million USD | 1.18% |
| 2020 Q1 | 100.54 Million USD | -10.22% |
| 2020 FY | 160.62 Million USD | 43.42% |
| 2020 Q3 | 158.74 Million USD | 24.37% |
| 2019 Q1 | 79.63 Million USD | 57.47% |
| 2019 Q3 | 98.7 Million USD | -1.51% |
| 2019 FY | 111.99 Million USD | 121.48% |
| 2019 Q4 | 111.99 Million USD | 13.47% |
| 2019 Q2 | 100.21 Million USD | 25.85% |
| 2018 Q2 | 45.29 Million USD | -4.27% |
| 2018 FY | 50.56 Million USD | 7.64% |
| 2018 Q4 | 50.56 Million USD | 4.31% |
| 2018 Q3 | 48.47 Million USD | 7.04% |
| 2018 Q1 | 47.31 Million USD | 0.71% |
| 2017 FY | 46.97 Million USD | -17.05% |
| 2017 Q4 | 46.97 Million USD | -4.63% |
| 2017 Q3 | 49.25 Million USD | -13.88% |
| 2017 Q2 | 57.19 Million USD | 4.97% |
| 2017 Q1 | 54.49 Million USD | -3.78% |
| 2016 FY | 56.63 Million USD | -33.11% |
| 2016 Q2 | 73.81 Million USD | -5.21% |
| 2016 Q1 | 77.87 Million USD | -8.03% |
| 2016 Q4 | 56.63 Million USD | -14.6% |
| 2016 Q3 | 66.31 Million USD | -10.16% |
| 2015 Q1 | 367.93 Million USD | 287.49% |
| 2015 FY | 84.66 Million USD | -10.83% |
| 2015 Q4 | 84.66 Million USD | 20.28% |
| 2015 Q3 | 70.39 Million USD | -2.04% |
| 2015 Q2 | 71.85 Million USD | -80.47% |
| 2014 FY | 94.95 Million USD | 153.46% |
| 2014 Q2 | 31.37 Million USD | -10.79% |
| 2014 Q1 | 35.17 Million USD | -6.12% |
| 2014 Q3 | 98.55 Million USD | 214.1% |
| 2014 Q4 | 94.95 Million USD | -3.65% |
| 2013 Q4 | 37.46 Million USD | 5.01% |
| 2013 FY | 37.46 Million USD | 12.1% |
| 2013 Q1 | 34.17 Million USD | 2.26% |
| 2013 Q2 | 34.7 Million USD | 1.54% |
| 2013 Q3 | 35.67 Million USD | 2.8% |
| 2012 Q4 | 33.41 Million USD | 1.93% |
| 2012 FY | 33.41 Million USD | -64.77% |
| 2012 Q2 | 26.81 Million USD | 0.0% |
| 2012 Q3 | 32.78 Million USD | 22.28% |
| 2011 FY | 94.86 Million USD | 396.58% |
| 2011 Q4 | 94.86 Million USD | 0.0% |
| 2010 Q4 | 19.1 Million USD | 0.0% |
| 2010 Q2 | 12.63 Million USD | 0.0% |
| 2010 FY | 19.1 Million USD | 5.44% |
| 2009 Q4 | 18.11 Million USD | 0.0% |
| 2009 FY | 18.11 Million USD | 23.92% |
| 2009 Q2 | 15.83 Million USD | 0.0% |
| 2008 Q4 | 14.62 Million USD | 0.0% |
| 2008 FY | 14.62 Million USD | 41.54% |
| 2007 FY | 10.32 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Absci Corporation | 58.3 Million USD | -328.058% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 29.27% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.838% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -7636.905% |
| Apollomics, Inc. | 14.15 Million USD | -1663.407% |
| 180 Life Sciences Corp. | 5.38 Million USD | -4532.733% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -4666.52% |
| Bicycle Therapeutics plc | 224.41 Million USD | -11.213% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -807.183% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -91.671% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -388.376% |
| Chimerix, Inc. | 19.74 Million USD | -1163.991% |
| CRISPR Therapeutics AG | 346.76 Million USD | 28.028% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -25.843% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -180.86% |
| Fortress Biotech, Inc. | 165.93 Million USD | -50.402% |
| Fortress Biotech, Inc. | 165.93 Million USD | -50.402% |
| Gritstone bio, Inc. | 125.91 Million USD | -98.203% |
| Allakos Inc. | 74.79 Million USD | -233.688% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 2.88% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -262.971% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 79.385% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1624.418% |
| Innoviva, Inc. | 568.55 Million USD | 56.103% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -35301.563% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2236.8% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -849.171% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -19109.292% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1797.909% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -914.285% |
| ImmuCell Corporation | 18.81 Million USD | -1226.466% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -784.203% |
| Incyte Corporation | 1.59 Billion USD | 84.326% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -348.914% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -61690.061% |
| Mustang Bio, Inc. | 17.61 Million USD | -1316.511% |
| MiMedx Group, Inc. | 96.33 Million USD | -159.083% |
| MEI Pharma, Inc. | 8.35 Million USD | -2887.133% |
| MacroGenics, Inc. | 154.2 Million USD | -61.844% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -14101.434% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1463.557% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -8016.661% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -61.911% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 64.222% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -192.386% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -3994.078% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -4842.079% |
| NextCure, Inc. | 14.99 Million USD | -1564.166% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -818.602% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -6074.542% |
| Onconetix, Inc. | 23.18 Million USD | -976.641% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -3637.831% |
| Opthea Limited | 264.6 Million USD | 5.679% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -343.848% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1961.803% |
| PDS Biotechnology Corporation | 33.25 Million USD | -650.395% |
| Precigen, Inc. | 41.64 Million USD | -499.306% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1993.399% |
| Prime Medicine, Inc. | 60.78 Million USD | -310.62% |
| PureTech Health plc | 125.58 Million USD | -98.733% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -238.329% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.488% |
| Replimune Group, Inc. | 113.21 Million USD | -120.445% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4384.811% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -71.095% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -6972.343% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 4.886% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3677.274% |
| Sesen Bio, Inc. | 30.98 Million USD | -705.496% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -202.761% |
| Solid Biosciences Inc. | 38.45 Million USD | -548.955% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -325.286% |
| SciSparc Ltd. | 1.59 Million USD | -15547.335% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 22.272% |
| TG Therapeutics, Inc. | 169.08 Million USD | -47.603% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -410.045% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -17183.587% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 57.563% |
| UroGen Pharma Ltd. | 243.52 Million USD | -2.485% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -303.621% |
| XOMA Corporation | 145.58 Million USD | -71.435% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -100.243% |
| AbCellera Biologics Inc. | 335.77 Million USD | 25.672% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -2453.458% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1658.19% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -609.481% |
| Precision BioSciences, Inc. | 140.92 Million USD | -77.104% |
| Dyadic International, Inc. | 2.34 Million USD | -10562.632% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -5938.592% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1434.618% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -2688.547% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -702.724% |
| IGM Biosciences, Inc. | 220.17 Million USD | -13.352% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -159.544% |
| Acelyrin, Inc. | 86.35 Million USD | -189.017% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -407.514% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -90.942% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -6972.668% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -65.403% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -64.723% |
| Senti Biosciences, Inc. | 52.57 Million USD | -374.739% |
| Mesoblast Limited | 188.79 Million USD | -32.192% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -38.048% |
| ChromaDex Corporation | 26.5 Million USD | -841.508% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2816.552% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 8.341% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -15271.553% |
| Seer, Inc. | 39.36 Million USD | -534.002% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 28.196% |
| Novavax, Inc. | 2.57 Billion USD | 90.297% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -3143.751% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -81.114% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -1254.545% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -162.498% |
| Celcuity Inc. | 51.45 Million USD | -385.082% |
| ContextLogic Inc. | 206 Million USD | -21.153% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 48.711% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -249.154% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 96.74% |
| Amarin Corporation plc | 279.58 Million USD | 10.734% |
| AnaptysBio, Inc. | 364.28 Million USD | 31.489% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1877.458% |
| Aptorum Group Limited | 5.25 Million USD | -4647.716% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 66.511% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 47.83% |
| Ardelyx, Inc. | 130.76 Million USD | -90.861% |
| Celularity Inc. | 102.92 Million USD | -142.473% |
| Omeros Corporation | 403.25 Million USD | 38.109% |
| Humacyte, Inc. | 114.67 Million USD | -117.633% |
| Immunocore Holdings plc | 228.15 Million USD | -9.387% |
| IO Biotech, Inc. | 17.55 Million USD | -1321.594% |
| GT Biopharma, Inc. | 6.63 Million USD | -3662.626% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1330.065% |
| Summit Therapeutics Inc. | 125.25 Million USD | -99.25% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -12659.458% |
| Pulmatrix, Inc. | 15.96 Million USD | -1463.459% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 0.492% |
| Evogene Ltd. | 17.99 Million USD | -1287.298% |
| CorMedix Inc. | 11.91 Million USD | -1994.184% |
| BioLineRx Ltd. | 50.7 Million USD | -392.239% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -2564.407% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -4314.132% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 90.83% |
| scPharmaceuticals Inc. | 57.26 Million USD | -335.855% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -1009.173% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -117.377% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2236.8% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3677.274% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -455.043% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -8595.993% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -3570.221% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -262.876% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -1225.693% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -433.976% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1914.648% |
| Daré Bioscience, Inc. | 26.32 Million USD | -847.878% |
| bluebird bio, Inc. | 424.62 Million USD | 41.224% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 86.795% |
| DBV Technologies S.A. | 42.8 Million USD | -483.119% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -95.299% |
| Galecto, Inc. | 5.89 Million USD | -4132.955% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -2532.925% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -809.629% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 5.603% |
| GlycoMimetics, Inc. | 6.9 Million USD | -3515.942% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 1.236% |
| ADMA Biologics, Inc. | 193.97 Million USD | -28.663% |
| Clene Inc. | 38.95 Million USD | -540.741% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -31.174% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1478.719% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -2160.707% |
| Soligenix, Inc. | 7.27 Million USD | -3330.629% |
| Century Therapeutics, Inc. | 175.94 Million USD | -41.852% |
| Kura Oncology, Inc. | 51.66 Million USD | -383.092% |
| Surrozen, Inc. | 8.14 Million USD | -2964.15% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -105.781% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -3673.518% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 1.197% |
| Autolus Therapeutics plc | 263.9 Million USD | 5.431% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -2280.986% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -432.154% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -243.924% |
| GRI Bio, Inc. | 2.69 Million USD | -9153.801% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -30727.523% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -592.149% |
| INmune Bio, Inc. | 18.86 Million USD | -1223.163% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 2.692% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -836.779% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9080.932% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -6858.695% |
| Jaguar Health, Inc. | 45.86 Million USD | -444.139% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -7508.377% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -326.952% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -399.85% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 5.726% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 69.676% |
| Verastem, Inc. | 71.18 Million USD | -250.601% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -546.936% |
| Histogen Inc. | 5.69 Million USD | -4280.814% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -5590.777% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 21.32% |
| Surrozen, Inc. | 8.14 Million USD | -2964.15% |
| Organovo Holdings, Inc. | 2.74 Million USD | -8982.06% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -79418.445% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -30082.918% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -96.942% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -2207.975% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -9471.998% |
| Kronos Bio, Inc. | 54.2 Million USD | -360.462% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1664.03% |
| Synaptogenix, Inc. | 5.52 Million USD | -4413.544% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -3654.137% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -10.026% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -46.716% |
| Exelixis, Inc. | 678.44 Million USD | 63.214% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -52.137% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 57.999% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1600.566% |
| ESSA Pharma Inc. | 3.49 Million USD | -7040.771% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -4804.565% |
| Avid Bioservices, Inc. | 275.66 Million USD | 9.465% |
| Insmed Incorporated | 1.66 Billion USD | 84.981% |
| MediWound Ltd. | 27.18 Million USD | -817.994% |
| OmniAb, Inc. | 87.4 Million USD | -185.555% |
| Alector, Inc. | 487.66 Million USD | 48.823% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 38.141% |
| Zai Lab Limited | 240.17 Million USD | -3.913% |
| AlloVir, Inc. | 45.01 Million USD | -454.426% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 60.389% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -715.658% |
| Aura Biosciences, Inc. | 29.22 Million USD | -753.919% |
| Immunic, Inc. | 25.36 Million USD | -883.818% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -260.47% |
| Veracyte, Inc. | 93.71 Million USD | -166.301% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -9437.875% |
| FibroGen, Inc. | 585.72 Million USD | 57.391% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1335.742% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -197.021% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -38115.307% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -4312.994% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -2944.34% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -197.035% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 90.468% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -765.918% |
| XBiotech Inc. | 8.39 Million USD | -2872.192% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1600.566% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -560.042% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1635.691% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -369.302% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 31.267% |
| Agenus Inc. | 462.29 Million USD | 46.014% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -828.34% |
| Theravance Biopharma, Inc. | 169 Million USD | -47.674% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 79.469% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 50.127% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 74.336% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -4038.129% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -91.484% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -67099.524% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -4742.327% |
| Lantern Pharma Inc. | 2.73 Million USD | -9009.634% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -487.581% |
| Ainos, Inc. | 7.39 Million USD | -3275.27% |
| Pluri Inc. | 34.11 Million USD | -631.634% |
| Prothena Corporation plc | 135.01 Million USD | -84.847% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -2.662% |
| Rallybio Corporation | 9.43 Million USD | -2544.924% |
| Kodiak Sciences Inc. | 213.59 Million USD | -16.847% |
| Cue Biopharma, Inc. | 24.44 Million USD | -920.965% |
| MeiraGTx Holdings plc | 319.99 Million USD | 22.006% |
| Annexon, Inc. | 47.11 Million USD | -429.681% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -158.97% |
| Moderna, Inc. | 4.57 Billion USD | 94.541% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -5019.487% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -225.222% |
| Blueprint Medicines Corporation | 918.64 Million USD | 72.832% |
| Immix Biopharma, Inc. | 3.72 Million USD | -6605.791% |
| CalciMedica, Inc. | 4.02 Million USD | -6096.003% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -100.454% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -190.822% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -9.73% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 10.158% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1482.293% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -391.425% |
| Nutriband Inc. | 1.07 Million USD | -23031.95% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -2247.174% |
| Vor Biopharma Inc. | 59.1 Million USD | -322.264% |
| Roivant Sciences Ltd. | 773.95 Million USD | 67.753% |
| Alkermes plc | 933.53 Million USD | 73.266% |
| ProKidney Corp. | 29.21 Million USD | -754.241% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -246.733% |
| Arcellx, Inc. | 339.75 Million USD | 26.542% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 86.787% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -66.986% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -182.194% |
| Atai Life Sciences N.V. | 49.16 Million USD | -407.658% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -701.145% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -1289.461% |
| MediciNova, Inc. | 3.89 Million USD | -6313.249% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -1265.365% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -16491.424% |
| GeoVax Labs, Inc. | 3.51 Million USD | -6990.439% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 37.176% |
| Biomea Fusion, Inc. | 30.69 Million USD | -713.213% |
| RenovoRx, Inc. | 4.46 Million USD | -5488.334% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -699.894% |
| Geron Corporation | 146.12 Million USD | -70.793% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1210.243% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -678.414% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -238.223% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -185.284% |
| Royalty Pharma plc | 6.29 Billion USD | 96.037% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -639.044% |
| Imunon, Inc. | 8.53 Million USD | -2825.703% |
| BioAtla, Inc. | 48.98 Million USD | -409.482% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -91.093% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1655.716% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -31.941% |
| Structure Therapeutics Inc. | 29.05 Million USD | -759.092% |
| 89bio, Inc. | 59.96 Million USD | -316.215% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -641.349% |
| aTyr Pharma, Inc. | 31.59 Million USD | -689.869% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -303.693% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -415.63% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -2959.26% |
| Akari Therapeutics, Plc | 4.58 Million USD | -5344.481% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1307.394% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 84.869% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -83.082% |
| Liquidia Corporation | 73.13 Million USD | -241.238% |
| Entera Bio Ltd. | 1.37 Million USD | -17998.26% |
| GH Research PLC | 6.7 Million USD | -3624.444% |
| Vericel Corporation | 127.7 Million USD | -95.431% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -550.223% |
| Xencor, Inc. | 283.55 Million USD | 11.985% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -8259.081% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9080.932% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -6542.712% |
| Vaxcyte, Inc. | 167.44 Million USD | -49.045% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -576.777% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -141.065% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -61690.061% |
| Portage Biotech Inc. | 4.45 Million USD | -5508.427% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -16491.424% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -982.755% |
| OncoCyte Corporation | 49.29 Million USD | -406.258% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -5933.038% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -31195.299% |
| Purple Biotech Ltd. | 10 Million USD | -2394.503% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -904.933% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -3656.962% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -53.127% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -4213.429% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1955.13% |
| United Therapeutics Corporation | 1.18 Billion USD | 78.889% |
| HilleVax, Inc. | 78.9 Million USD | -216.282% |
| Silo Pharma, Inc. | 1.56 Million USD | -15803.892% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -18586.862% |
| Pharming Group N.V. | 244.07 Million USD | -2.254% |
| Tharimmune, Inc. | 1.81 Million USD | -13650.34% |
| Genprex, Inc. | 3.25 Million USD | -7569.301% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -1061.3% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -820.296% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -419.71% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -121052.913% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -69507.138% |
| OKYO Pharma Limited | 7.42 Million USD | -3263.161% |
| Savara Inc. | 37.19 Million USD | -571.045% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -760.159% |
| Curis, Inc. | 57.61 Million USD | -333.2% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -536.674% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1098.785% |
| BeiGene, Ltd. | 2.23 Billion USD | 88.827% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1073.146% |
| Erasca, Inc. | 78.61 Million USD | -217.481% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -37988.4% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -37988.4% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -3467.906% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -14970.954% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1362.068% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -584.592% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -348.594% |
| Adicet Bio, Inc. | 37.12 Million USD | -572.346% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 59.596% |
| Aditxt, Inc. | 28.53 Million USD | -774.733% |
| Adagene Inc. | 45.16 Million USD | -452.532% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -138014.897% |
| Quantum-Si incorporated | 26.63 Million USD | -837.16% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -8103.125% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -117.095% |
| Compugen Ltd. | 55.77 Million USD | -347.468% |
| Generation Bio Co. | 171.63 Million USD | -45.415% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -2060.823% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -496.627% |
| Invivyd, Inc. | 51.71 Million USD | -382.616% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -171.345% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -3736.516% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -230.58% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -24344.172% |
| 2seventy bio, Inc. | 310.12 Million USD | 19.525% |
| Instil Bio, Inc. | 99.8 Million USD | -150.073% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -590.715% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -18212.835% |
| GeoVax Labs, Inc. | 3.51 Million USD | -6990.439% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1949.113% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1946.569% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -372.313% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 32.521% |
| Evaxion Biotech A/S | 17.61 Million USD | -1316.633% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -55.084% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -62.923% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -1055.707% |
| Cingulate Inc. | 10.36 Million USD | -2308.824% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -8975.455% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -569.245% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -904.366% |
| Clearmind Medicine Inc. | 3.61 Million USD | -6813.42% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -430.525% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -996.564% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1143.461% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -6.106% |
| ImmunityBio, Inc. | 1.09 Billion USD | 77.111% |
| Korro Bio, Inc. | 51.75 Million USD | -382.252% |
| Kineta, Inc. | 7.22 Million USD | -3355.76% |
| BioVie Inc. | 9.7 Million USD | -2472.373% |
| Codexis, Inc. | 49.94 Million USD | -399.69% |
| Celularity Inc. | 102.92 Million USD | -142.473% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -122.044% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -159.307% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -72199.924% |
| Cibus, Inc. | 206.11 Million USD | -21.084% |
| IN8bio, Inc. | 8.77 Million USD | -2745.132% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -178.727% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1723.179% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 90.413% |
| Eyenovia, Inc. | 19.78 Million USD | -1161.736% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -40.934% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3149.251% |
| Elevation Oncology, Inc. | 34.28 Million USD | -628.006% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -935.624% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1997.621% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -1.643% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -2509.798% |
| Moolec Science SA | 13.94 Million USD | -1689.664% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -478.363% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -393.895% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -527.451% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -2893.583% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -84672.389% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -10044.162% |
| Humacyte, Inc. | 114.67 Million USD | -117.633% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -843.109% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -20767.475% |
| Genelux Corporation | 8.42 Million USD | -2864.074% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -3540.242% |
| Notable Labs, Ltd. | 4.42 Million USD | -5537.565% |
| Immunovant, Inc. | 48.95 Million USD | -409.805% |
| Quantum-Si incorporated | 26.63 Million USD | -837.16% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -7943.023% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -237.898% |
| Acasti Pharma Inc. | 11.55 Million USD | -2059.514% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -1003.937% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -976.497% |
| PepGen Inc. | 34.63 Million USD | -620.669% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -3473.525% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2816.552% |
| Immuneering Corporation | 12 Million USD | -1978.345% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -79418.445% |
| Belite Bio, Inc | 4.21 Million USD | -5826.739% |
| XOMA Corporation | 145.58 Million USD | -71.435% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -10179.036% |
| Bionomics Limited | 10.15 Million USD | -2356.756% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -989.229% |
| uniQure N.V. | 624.01 Million USD | 60.005% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -138014.897% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -46.65% |
| Forte Biosciences, Inc. | 3.66 Million USD | -6707.829% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -95675.626% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -3599.051% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3149.251% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1335.742% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -2261.611% |
| Altimmune, Inc. | 16.54 Million USD | -1408.827% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -5020.538% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -989.229% |
| Peak Bio, Inc. | 20.75 Million USD | -1102.576% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -125.935% |
| Benitec Biopharma Inc. | 4.96 Million USD | -4929.726% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -58.116% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -231.996% |
| Zura Bio Limited | 21.29 Million USD | -1072.154% |
| PolyPid Ltd. | 17.46 Million USD | -1328.755% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -231.996% |
| argenx SE | 444.95 Million USD | 43.91% |
| Immunome, Inc. | 28.65 Million USD | -770.874% |
| Verona Pharma plc | 58.84 Million USD | -324.152% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1624.418% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1579.622% |
| CervoMed Inc. | 2.59 Million USD | -9514.766% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1859.603% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -2269.008% |
| Moolec Science SA | 13.94 Million USD | -1689.664% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -10549.651% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1987.446% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1867.636% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -541.12% |
| Achilles Therapeutics plc | 19.08 Million USD | -1207.565% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -996.564% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1619.902% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 37.804% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -668.562% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1812.585% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -4651.095% |
| Beam Therapeutics Inc. | 478.38 Million USD | 47.83% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 37.285% |
| AEON Biopharma, Inc. | 159.88 Million USD | -56.093% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -816.612% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -861.346% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -3182.924% |
| NeurAxis, Inc. | 1.91 Million USD | -12948.043% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -27.505% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1771.859% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -958.06% |
| Palisade Bio, Inc. | 2.73 Million USD | -9011.902% |
| Nutriband Inc. | 1.07 Million USD | -23031.95% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -29.948% |
| Neurogene Inc. | 36.54 Million USD | -582.85% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -10107.566% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -423.767% |
| Athira Pharma, Inc. | 30.05 Million USD | -730.339% |
| HCW Biologics Inc. | 15.05 Million USD | -1558.092% |
| XOMA Corporation | 145.58 Million USD | -71.435% |
| Nektar Therapeutics | 267.04 Million USD | 6.542% |
| Arvinas, Inc. | 644.6 Million USD | 61.282% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1307.394% |
| Merus N.V. | 102.15 Million USD | -144.32% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -70.533% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -162.379% |
| Rezolute, Inc. | 11.73 Million USD | -2026.939% |
| Clene Inc. | 38.95 Million USD | -540.741% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -8665.075% |
| BeyondSpring Inc. | 48.26 Million USD | -417.05% |
| Synlogic, Inc. | 32.89 Million USD | -658.702% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1607.897% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -15173.868% |
| Peak Bio, Inc. | 20.75 Million USD | -1102.576% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -293.285% |
| Krystal Biotech, Inc. | 39.71 Million USD | -528.431% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 33.737% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -150.655% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -57575.065% |
| MannKind Corporation | 721.36 Million USD | 65.402% |
| Ikena Oncology, Inc. | 22.33 Million USD | -1017.417% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -11864.286% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -143.274% |
| Gossamer Bio, Inc. | 249.14 Million USD | -0.172% |
| CohBar, Inc. | 1.03 Million USD | -24045.3% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -2234.877% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1210.243% |
| Legend Biotech Corporation | 589.93 Million USD | 57.694% |
| Mural Oncology plc | 37.92 Million USD | -558.023% |
| Disc Medicine, Inc. | 22.87 Million USD | -991.038% |
| Champions Oncology, Inc. | 28.03 Million USD | -790.227% |
| REGENXBIO Inc. | 262.22 Million USD | 4.825% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -7329.26% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1891.184% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1758.114% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1076.963% |
| Vaxart, Inc. | 34.02 Million USD | -633.505% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1124.051% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -774.723% |
| Longeveron Inc. | 5.33 Million USD | -4576.316% |
| Repare Therapeutics Inc. | 41.81 Million USD | -496.798% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 89.624% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -313.423% |
| Revolution Medicines, Inc. | 262.39 Million USD | 4.886% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -11745.04% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -2793.288% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -2014.863% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1677.22% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -11502.743% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 95.154% |
| Denali Therapeutics Inc. | 122.96 Million USD | -102.968% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4384.811% |
| Veru Inc. | 32.81 Million USD | -660.605% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -3533.353% |
| Cingulate Inc. | 10.36 Million USD | -2308.824% |
| Passage Bio, Inc. | 39.26 Million USD | -535.666% |
| Context Therapeutics Inc. | 4.19 Million USD | -5854.007% |
| Exicure, Inc. | 8.54 Million USD | -2819.347% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -745.788% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -2280.078% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -1032.322% |
| Nuvalent, Inc. | 31.82 Million USD | -684.26% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -3823.132% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -296.013% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -1286.528% |
| OmniAb, Inc. | 87.4 Million USD | -185.555% |
| Anew Medical, Inc. | 8.24 Million USD | -2928.162% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -551.817% |
| Lipocine Inc. | 2.63 Million USD | -9383.67% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -849.966% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -520.648% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -836.779% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -189.685% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -4520.904% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -201.612% |
| Ocugen, Inc. | 23.98 Million USD | -940.633% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -437.796% |
| Q32 Bio Inc. | 233.12 Million USD | -7.055% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -2652.868% |
| Alumis Inc. Common Stock | 53.5 Million USD | -366.478% |
| Equillium, Inc. | 27.95 Million USD | -792.71% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -20.806% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -4335.576% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -3969.4% |
| Dominari Holdings Inc. | 4.63 Million USD | -5284.574% |
| Edesa Biotech, Inc. | 1.84 Million USD | -13451.802% |
| vTv Therapeutics Inc. | 29.56 Million USD | -744.1% |
| Bio-Techne Corporation | 744.34 Million USD | 66.47% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -97.92% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 27.545% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -515.096% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -761.881% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -170.22% |
| Nkarta, Inc. | 105.6 Million USD | -136.34% |
| BioCardia, Inc. | 4.59 Million USD | -5337.364% |
| Iterum Therapeutics plc | 32.66 Million USD | -664.114% |